Barclays PLC Rx Sight, Inc. Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Rx Sight, Inc. stock. As of the latest transaction made, Barclays PLC holds 64,807 shares of RXST stock, worth $1.99 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

64,807

Previous 58,786 10.24%

Holding current value

$1.99 Million

Previous $2.91 Million 23.33%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$33.66 - $54.73 $202,666 - $329,529	6,021 Added 10.24%	64,807 $2.23 Million
Q3 2024 Nov 15, 2024	BUY	$40.78 - $57.04 $1.91 Million - $2.67 Million	46,783 Added 389.76%	58,786 $2.91 Million
Q2 2024 Aug 14, 2024	SELL	$50.42 - $64.29 $682,838 - $870,679	-13,543 Reduced 53.01%	12,003 $722,000
Q1 2024 May 15, 2024	SELL	$35.51 - $57.92 $641,417 - $1.05 Million	-18,063 Reduced 41.42%	25,546 $1.32 Million
Q4 2023 Feb 15, 2024	BUY	$20.91 - $40.9 $728,964 - $1.43 Million	34,862 Added 398.56%	43,609 $1.76 Million
Q3 2023 Nov 07, 2023	SELL	$27.05 - $33.37 $8,628 - $10,645	-319 Reduced 3.52%	8,747 $244,000
Q2 2023 Aug 03, 2023	SELL	$16.37 - $28.9 $48,389 - $85,428	-2,956 Reduced 24.59%	9,066 $261,000
Q1 2023 May 04, 2023	BUY	$12.58 - $16.68 $81,681 - $108,303	6,493 Added 117.44%	12,022 $201,000
Q4 2022 Feb 13, 2023	BUY	$9.93 - $14.2 $46,234 - $66,115	4,656 Added 533.33%	5,529 $70,000
Q3 2022 Nov 03, 2022	SELL	$11.19 - $15.85 $1,790 - $2,536	-160 Reduced 15.49%	873 $10,000
Q2 2022 Aug 12, 2022	SELL	$10.61 - $16.66 $19,299 - $30,304	-1,819 Reduced 63.78%	1,033 $15,000
Q1 2022 May 16, 2022	BUY	$8.97 - $14.03 $25,582 - $40,013	2,852 New	2,852 $35,000

Others Institutions Holding RXST

# of Institutions

222

Shares Held

33.4M

Call Options Held

531K

Put Options Held

50.1K

View Full List

About RxSight, Inc.

Ticker RXST
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 27,638,900
Market Cap $849M
Description
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. T...

More about RXST

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account